The midpoint demonstrates ~32% growth YoY, fueled by new Lilly medicines like Zepbound, Mounjaro, Jaypirca, Ebglyss, Omvoh and Kisunla, approvals of new indications for existing Lilly medicines ...

For instance, multiple FDA approvals, like those for Zepbound and Omvoh, significantly expanded the company's treatment portfolio. Another factor has been the robust financial results, with sales ...

It might become a family affair in East Lansing. On Thursday, On3 reported that four-star athlete Salesi Moa set an early official visit with Michigan State for the weekend of April 2. Moa's ...

Crested Moa (Pachyornis australis). Credit: From the series- ExSnct Birds of New Zealand., 2005, Masterton, by Paul MarSnson. Te Papa (2006-0010-1-19). CC BY-NC-ND 4.0, edited New research reveals ...

The U.S. Food and Drug Administration has approved Eli Lilly's Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn's disease in adults. Crohn's disease, also known as ...

These new medicines include Alzheimer's disease treatment Kisunla, ulcerative colitis medication Omvoh, and cancer drug Jaypirca. Of course, Lilly's most important new products are diabetes ...

The European Commission will review the CHMP recommendation to determine issuing an expanded Marketing Authorisation, and a decision is expected in due course. 2 J&J Data on file (RF-452642). European ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), Eli ...